Skip to main content
. Author manuscript; available in PMC: 2009 May 13.
Published in final edited form as: Int J Cancer. 2008 Sep 15;123(6):1357–1363. doi: 10.1002/ijc.23676

Figure 5.

Figure 5

Comparison of complement inhibitor expression on tumors from patients with either high or low anti-MUC1 antibody titers. Patients were divided into 2 groups based on their anti-MUC1 antibody levels. Group A represents patients with antibody levels (either IgM or IgG) at least one standard deviation higher than the average levels from normal individuals (n = 12), and Group B represents remaining patients (n = 10). Bladder tumors from patients with high levels of anti-MUC1 antibodies (Group A) had significantly higher mRNA levels of CD46, CD55 and CD46 (p < 0.05) than tumors from patients with low titer anti-MUC1 antibodies (Group B). Mean ± SD.